The Company is a Korea-based company mainly engaged in the development of pharmaceutical products. The Company s product portfolio consists of stem cell therapy products including Furestem-AD which used for treating atopic dermatitis, Furestem-RA which used for treating rheumatoid arthritis, Furestem-CD which used for treating crohn's disease, stem cell conditioned medias which used as raw materials of cosmetics including umbilical cord blood-derived stem cell conditioned medias (USC-CMs) and others and stem cell culture medias including KSB-3 Complete Kit and others. The Company distributes its products within domestic market and to overseas markets. The Company was established on October 29, 2010. The Company share was listed on the Korea Securities Dealers Automated Quotation System ( KOSDAQ ) on December 21, 2015.
Headquarters
17F, Sinan Bldg., 512, Teheran-Ro, Gangnam-Gu
Seoul; Seoul;
Contact Details: Purchase the Kangstem Biotech Co., Ltd. report to view the information.
Website: http://www.kangstem.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service